New review: smarter screening, sharper surgery, and what still needs work.

Colorectal cancer (CRC) is the world’s third most common cancer and the second leading cause of cancer deaths—around 1.9 million new cases and 935,000 deaths in 2020. Routine screening now starts at age 45 for average‑risk adults in the U.S., because catching disease early saves lives.  

A new narrative review pulls together the fast‑moving evidence on how artificial intelligence (AI) is being woven into nearly every step of CRC care—from finding tiny precancerous polyps to guiding complex operations and personalizing follow‑up. The authors analyzed 122 studies published over the past decade. Their bottom line: AI is already improving key parts of care, but bigger, multi‑center trials and careful roll‑out are needed before it becomes the default everywhere.  

Where AI is helping today

• Screening & detection. In colonoscopy, computer‑aided systems can flag subtle polyps in real time and lower “miss” rates, which in turn pushes up adenoma detection rates—two measures closely tied to preventing cancers. AI can also support “optical diagnosis,” helping endoscopists decide on the spot whether a tiny lesion is safe to leave alone, potentially avoiding unnecessary polyp removals.    
• Reading images & pathology. Deep‑learning tools are being tested to read whole‑slide pathology images, estimate lymph‑node spread, and predict microsatellite instability (MSI)—a genetic signal that can change treatment choices. Radiology “radiomics” models and PET/CT‑based machine‑learning approaches are also being studied to improve staging and to spot liver metastases earlier.  
• Surgery. In operating rooms, AI‑enabled robotic platforms are delivering shorter hospital stays, lower conversion to open surgery, and favorable short‑term outcomes versus standard laparoscopy in several studies, although results can depend on the team and center. Some research also suggests a lower inflammatory stress response after robotic colorectal procedures.    

The roadblocks

Despite momentum, the review flags important caveats:

• Evidence gaps. Many studies are single‑center or small; more randomized, multi‑center trials are needed to confirm real‑world benefits and cost‑effectiveness.  
• People and places matter. Outcomes often hinge on institutional experience, not just the surgeon, underscoring the need for standardized training and quality programs.  
• Equity & access. High costs and uneven availability risk widening disparities unless health systems plan for fair access to AI‑assisted tools (for example, robotic surgery).  
• Privacy, bias, and clinical judgment. Patient data must be protected; algorithms should be audited for bias; and clinicians should avoid over‑reliance on AI—tools should augment, not replace, expert judgment.  

What this means for you

• Don’t delay screening. If you’re 45 or older (or younger with risk factors), get screened—today’s tools, including AI‑assisted colonoscopy in some centers, can find more precancerous lesions.    
• Ask smart questions. If AI‑assisted options are offered (for detection, pathology, or surgery), ask how they’re used, how teams are trained, and how your data are protected.  
• Expect steady progress, not magic. The review’s message is hopeful but measured: AI is raising the floor on detection and precision in CRC care, while the field works to prove—and fairly deliver—its full potential.  

Source: “A Narrative Review on the Role of Artificial Intelligence (AI) in Colorectal Cancer Management,” Cureus (Feb 24, 2025).  

Editor’s note: This article is for information only and is not a substitute for professional medical advice.